预约演示

Innate shelves lacutamab monotherapy plans in peripheral T cell lymphoma

2024-03-22

交易

临床2期临床结果临床1期免疫疗法

Innate announced the decision to not reopen the trial’s recruitment in its full-year earnings report. Image credit: Shutterstock/CI Photos.

Innate has dropped plans to evaluate lacutamab as a monotherapy in KIR3DL2-expressing refractory/relapsing peripheral T cell lymphoma (r/r PTCL) following disappointing data from a Phase Ib trial.

Innateench biotech, which has both PTlacutamabtaneous T cell lymphoKIR3DL2-expressing refractory/relapsing peripheral T cell lymphoma (r/r PTCL)KIR3DL2-expressinges for its anti-KIR3DL2 antibody, highlighted the “prespecified threshold for meaningful activity not being reached” as the reason for the trial’s (NCT05321147) termination.

Innate announced the decision to noPTCLopen cutaneous T cell lymphoma (CTCL)ull-year earnings reanti-KIR3DL2 antibodyarch.

Innatemab has had a bumpy clinical journey. The US Food and Drug Administration (FDA) placed a partial clinical hold on the drug’s trials in December 2023, following a death from a rare haematologic disorder in one of Innate’s CTCL trials evaluating lacutamab. The hold was lifted a month later after an analysis found that Innate’s compound was not to blame.

Lacutamab is the end of the road for lacutamab as aFood and Drug Administration (FDA)ill investigating its potential use in the cancer type as a combination with the chemotherapy GEMOX –haematologic disordernation withInnateplaCTCL The Phase II KILT lacutamabT04984837) is being led by the Lymphoma Study Association (LYSA).Innate

AnGes files patent for crispr-based method for modifying mutant lRRK2 gene in cells

AnGesctis files patent for engineered T-cells for immunotherapy lRRK2inhibited B2M expression

Innate will also press ahead with its CTCL programme as planned. In December 2023, the biotech reported positive final data for its Phase II TELLOMAK study (NCT03902184) in patients with Sézary syndrome, a type of CTCL. The results included a 37.5% objective response rate in patients treated with a median of five prior lines of therapy.

Innate has also reported positive interim data from a Phase I trial investigatiB2Mthe drug in patients with mycosis fungoides (MF), also a type of CTCL. The company expects to present topline results from the study later this year.

In the financial results release, Innate’s CEO Hervé Brailly also pointed towards recent successes in its natural killer (NK) cell engager programme.

Innate has become somewhat of a specialist in NK cell engagers through its ANKET platform. The biotech has a range of NK-targeting therapies in clinical trials being tested as cancer treaSézary syndromellaboration CTCL Sanofi. The big pharma has licensed four NK cell engagers from Innate through a €400m ($437.5m) initial deal and a €15m ($16.4m) expansion.

Innate view to Innate’s plans for 2024, Brailly said: “We expect notable milestones including final results mycosis fungoides (MF)e II trial with lCTCLamab in mycosis fungoides, and progressing our first proprietary ADC programme, IPH45 towards an IND filing.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构